CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Mariz, Fernanda Pinto; Carvalho, Luciana Rodrigues; Araujo, Alexandra Prufer De Queiroz Campos; Mello, Wallace De; Ribeiro, Márcia Gonçalves; Cunha, Maria Do Carmo Soares Alves; Cabello, Pedro Hernan; Riederer, Ingo; Negroni, Elisa; Desguerre, Isabelle; Veras, Mariana; Yada, Erica; Allenbach, Yves; Benveniste, Olivier; Voit, Thomas; Mouly, Vincent; Barbosa, Suse Dayse Silva; Butler-Browne, Gillian; Savino, Wilson.
Artículo en Inglés | ARCA | ID: arc-13053

Documentos relacionados

  1. An update on Becker muscular dystrophy.
  2. [Chinese guidelines on the diagnosis of dystrophinopathy].
  3. Development of respiratory care guidelines for Duchenne muscular dystrophy in the UK: key recommendations for clinical practice.
  4. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.
  5. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.
  6. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. Reply.
  7. Exon Skipping Therapy.
  8. Comprehensive analysis of m<sup>6</sup>A regulators characterized by the immune microenvironment in Duchenne muscular dystrophy.
  9. Interplay between myofibers and pro-inflammatory macrophages controls muscle damage in mdx mice.
  10. Social cognition in two brothers with Becker muscular dystrophy: an exploratory study revealing divergent behavioral phenotypes.